Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- Shares of ACELYRIN, INC. (Nasdaq: SLRN) soared 16% following the company’s confirmation of an unsolicited buyout proposal from Concentra Biosciences. The late-stage clinical biopharma firm, specializing in immunology treatments, is currently poised for a merger with Alumis Inc. (Nasdaq: ALMS), anticipated to finalize in the second quarter of 2025.
The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future licensing or sale of the company’s development programs or intellectual property. This proposal comes as ACELYRIN is navigating through a previously announced merger agreement with Alumis, which remains subject to stockholder approval and other customary closing conditions.
ACELYRIN’s board has expressed its dedication to fulfilling its fiduciary duties, acting in the best interests of all shareholders, and adhering to the terms of its current merger agreement with Alumis. The company has advised its shareholders that no immediate action is required on their part in response to the buyout interest.
Financial advisory for ACELYRIN is being provided by Guggenheim Securities, LLC, with Fenwick & West LLP and Paul Hastings LLP serving as legal counsel. The unsolicited indication of interest from Concentra Biosciences has introduced a new dynamic to ACELYRIN’s future, potentially reshaping the company’s trajectory ahead of the planned merger with Alumis.
As the situation develops, ACELYRIN has pledged to keep shareholders informed of any significant updates. The market’s reaction to the news of potential acquisition interest reflects investor anticipation of the strategic decisions that will shape the company’s path forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.